3 results
Approved WMORecruiting
To evaluate recurrent dysphagia, due to tissue overgrowth or migration, of the SX-Ella stent Esophageal HV in patients with dysphagia from inoperable carcinoma of the distal esophagus or cardia.
Approved WMORecruiting
The primary objective of this study is to compare, in a randomized phase III trial, the effect of 10-day decitabine at a dose of 20 mg/m2 versus conventional induction chemotherapy (*3+7*) on OS in older AML patients.
Approved WMORecruiting
Primary ObjectivesPhase 1 portion:• to determine the maximum tolerable dose (MTD) of cytarabine (up to 2 g/m2/day x 5) that can be administered on Days 8-12 following treatment with DACOGEN 20 mg/m2/day on Days 1-5 of a 28 day cycle. • to determine…